Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]
, 2017 Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W +11 more
core +1 more source
Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy
Microorganisms, 2023 Influenza infection is serious and debilitating for humans and animals. The influenza virus undergoes incessant mutation, segment recombination, and genome reassortment.
Sania Batool +2 more
doaj +1 more source
Optimal personalized therapies in colon-cancer induced immune response using a Fokker-Planck framework [PDF]
arXiv, 2022 In this paper, a new stochastic framework to determine optimal combination therapies in colon cancer-induced immune response is presented. The dynamics of colon cancer is described through an It\"o stochastic process, whose probability density function evolution is governed by the Fokker-Planck equation.
arxiv
Cancer immunology research, 2018 Immunotherapies such as checkpoint-blocking antibodies and adoptive cell transfer are emerging as treatments for a growing number of cancers. Despite clinical activity of immunotherapies across a range of cancer types, the majority of patients fail to ...
Jonathan A. Trujillo +3 more
semanticscholar +1 more source
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. [PDF]
, 2016 BackgroundLeiomyosarcoma (LMS) is a common type of soft tissue sarcoma that responds poorly to standard chemotherapy. Thus the goal of this study was to identify novel selective therapies that may be effective in leiomyosarcoma by screening cell lines ...
Al-Awar, Rima +11 more
core +2 more sources
Principled Drug-Drug Interaction Terms for Bayesian Logistic Regression Models of Drug Safety in Oncology Phase I Combination Trials [PDF]
arXiv, 2023 In Oncology, trials evaluating drug combinations are becoming more common. While combination therapies bring the potential for greater efficacy, they also create unique challenges for ensuring drug safety. In Phase-I dose escalation trials of drug combinations, model-based approaches enable efficient use of information gathered, but the models need to ...
arxiv
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Cancers, 2018 Cancer drug resistance is an enormous problem. It is responsible for most relapses in cancer patients following apparent remission after successful therapy.
M. Leary +3 more
semanticscholar +1 more source
Optimized Treatment Schedules for Chronic Myeloid Leukemia
, 2016 Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David +4 more
core +3 more sources
D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. [PDF]
, 2013 The goal of this review is to examine the clinical studies on d-cycloserine, a partial glutamatergic N-methyl-D-aspartate agonist, as an augmentation strategy for exposure procedures during cognitive behavioral therapy for anxiety disorders.
Boettcher, Hannah +2 more
core +1 more source
Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy.
American Journal of Hypertension, 2013 BACKGROUND The use of fixed-dose combinations (FDCs) has been increasing since the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended using ≥2 drugs as the first-line drug
S. Hong, Junling Wang, Jun Tang
semanticscholar +1 more source